Floatz Rating
B61/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03581292CT.gov Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | — | Active Not Recruiting | — | — | — |
NCT01514201CT.gov Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anaplastic Astrocytoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Veliparib (this asset) | National Cancer Institute (NCI) | P2 | B · 61 |
| Irinotecan | City of Hope Medical Center | P2/3 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BBB |
| (+)-Vincristine | Novartis Pharmaceuticals | P2/3 | BB |
| Carboplatin | Oliver Jonas | P2 | BB |
| Trametinib | National Cancer Institute (NCI) | P4 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P1/2 | BB |
| Ziv-Aflibercept | National Cancer Institute (NCI) | P2 | B |
| Temsirolimus | Andrew B Lassman, MD | P1/2 | B |
+42 more in the Anaplastic Astrocytoma cohort
Other indications for Veliparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BBB · 74 |
| Small Cell Lung Carcinoma | — | P2 | BB · 71 |
| Triple-Negative Breast Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Veliparib in Anaplastic Astrocytoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/veliparib-anaplastic-astrocytoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →